CNX Therapeutics signs in-licensing deals for five products
CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.
The products are injectable antibiotics and are all used in a hospital setting for the treatment of a range of infections in adults and children.
- Ceftazidime 1 g powder for solution for injection or infusion
- Ceftazidime 2 g powder for solution for injection or infusion
- Ceftriaxone 1 g Powder for solution for injection or infusion
- Ceftriaxone 2 g Powder for solution for injection or infusion
- Meropenem 2 g powder for solution for infusion
These deals nicely complements our portfolio of hospital injectable products and strengthens our position within this market, supporting our goal of being a leading European provider of essential medicines.
Ceftazidime and ceftriaxone are on the WHO Essential Medicines List (2023), and our ability to supply these products to patients supports our commitment to having a positive impact on health and well-being.
Jeremy Devaney, Vice President of Commercial Operations says: “The in-licensing of these important medicines strengthens our existing portfolio and supports our vision of being a partner of choice for the commercialisation of injectable hospital products.
We are excited to extend our partnership with Venus Pharma and the growth of our collaboration demonstrates our shared commitment to improving the lives of patients through the supply of essential medicines.”
